Tissue | Expression Dynamics | Abbreviation |
Cervix | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Cervix/CADPS2_pca_on_diff_genes.png) | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/CADPS2_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/CADPS2_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Endometrium | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Endometrium/CADPS2_pca_on_diff_genes.png) | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/CADPS2_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/CADPS2_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/CADPS2_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00510473 | Colorectum | FAP | positive regulation of secretion | 67/2622 | 310/18723 | 1.59e-04 | 2.43e-03 | 67 |
GO:19035322 | Colorectum | FAP | positive regulation of secretion by cell | 62/2622 | 282/18723 | 1.67e-04 | 2.52e-03 | 62 |
GO:00459213 | Colorectum | FAP | positive regulation of exocytosis | 22/2622 | 86/18723 | 3.11e-03 | 2.33e-02 | 22 |
GO:00171572 | Colorectum | FAP | regulation of exocytosis | 41/2622 | 202/18723 | 8.51e-03 | 4.95e-02 | 41 |
GO:00990033 | Colorectum | CRC | vesicle-mediated transport in synapse | 45/2078 | 200/18723 | 2.67e-06 | 1.25e-04 | 45 |
GO:00995042 | Colorectum | CRC | synaptic vesicle cycle | 39/2078 | 181/18723 | 3.43e-05 | 8.71e-04 | 39 |
GO:00230611 | Colorectum | CRC | signal release | 72/2078 | 463/18723 | 1.95e-03 | 1.96e-02 | 72 |
GO:00459214 | Colorectum | CRC | positive regulation of exocytosis | 19/2078 | 86/18723 | 2.44e-03 | 2.31e-02 | 19 |
GO:19035323 | Colorectum | CRC | positive regulation of secretion by cell | 47/2078 | 282/18723 | 2.91e-03 | 2.64e-02 | 47 |
GO:00510474 | Colorectum | CRC | positive regulation of secretion | 50/2078 | 310/18723 | 4.31e-03 | 3.47e-02 | 50 |
GO:00171573 | Colorectum | CRC | regulation of exocytosis | 35/2078 | 202/18723 | 5.03e-03 | 3.86e-02 | 35 |
GO:00068872 | Colorectum | CRC | exocytosis | 55/2078 | 352/18723 | 5.62e-03 | 4.24e-02 | 55 |
GO:00990034 | Lung | IAC | vesicle-mediated transport in synapse | 39/2061 | 200/18723 | 2.71e-04 | 4.49e-03 | 39 |
GO:00995043 | Lung | IAC | synaptic vesicle cycle | 33/2061 | 181/18723 | 2.47e-03 | 2.33e-02 | 33 |
GO:009900311 | Lung | AIS | vesicle-mediated transport in synapse | 42/1849 | 200/18723 | 1.87e-06 | 1.10e-04 | 42 |
GO:009950411 | Lung | AIS | synaptic vesicle cycle | 36/1849 | 181/18723 | 3.42e-05 | 1.05e-03 | 36 |
GO:009900321 | Lung | MIAC | vesicle-mediated transport in synapse | 20/967 | 200/18723 | 3.64e-03 | 4.60e-02 | 20 |
GO:19035324 | Prostate | BPH | positive regulation of secretion by cell | 62/3107 | 282/18723 | 1.07e-02 | 4.45e-02 | 62 |
GO:190353211 | Prostate | Tumor | positive regulation of secretion by cell | 67/3246 | 282/18723 | 3.53e-03 | 1.82e-02 | 67 |
GO:00510476 | Prostate | Tumor | positive regulation of secretion | 71/3246 | 310/18723 | 6.95e-03 | 3.13e-02 | 71 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
CADPS2 | SNV | Missense_Mutation | novel | c.582N>C | p.Leu194Phe | p.L194F | Q86UW7 | protein_coding | deleterious(0) | probably_damaging(0.994) | TCGA-5L-AAT1-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | letrozol | SD |
CADPS2 | SNV | Missense_Mutation | novel | c.676N>A | p.Leu226Ile | p.L226I | Q86UW7 | protein_coding | tolerated(0.42) | benign(0.388) | TCGA-A2-A25A-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Cytoxan | SD |
CADPS2 | SNV | Missense_Mutation | | c.2339N>T | p.Ser780Leu | p.S780L | Q86UW7 | protein_coding | deleterious(0.03) | possibly_damaging(0.454) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
CADPS2 | SNV | Missense_Mutation | novel | c.2371G>T | p.Ala791Ser | p.A791S | Q86UW7 | protein_coding | tolerated(0.35) | benign(0.15) | TCGA-AC-A3W5-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | docetaxel | CR |
CADPS2 | SNV | Missense_Mutation | novel | c.3880N>A | p.Glu1294Lys | p.E1294K | Q86UW7 | protein_coding | tolerated_low_confidence(0.06) | benign(0.067) | TCGA-AC-A5XS-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | femara | SD |
CADPS2 | SNV | Missense_Mutation | novel | c.1039N>C | p.Asp347His | p.D347H | Q86UW7 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-AC-A6IW-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
CADPS2 | SNV | Missense_Mutation | novel | c.1151G>A | p.Arg384Gln | p.R384Q | Q86UW7 | protein_coding | deleterious(0) | probably_damaging(0.978) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
CADPS2 | SNV | Missense_Mutation | | c.1522N>T | p.Arg508Cys | p.R508C | Q86UW7 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-BH-A0AV-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | CR |
CADPS2 | SNV | Missense_Mutation | | c.1885G>C | p.Gly629Arg | p.G629R | Q86UW7 | protein_coding | deleterious(0) | possibly_damaging(0.67) | TCGA-BH-A0BP-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
CADPS2 | SNV | Missense_Mutation | | c.769N>T | p.Leu257Phe | p.L257F | Q86UW7 | protein_coding | deleterious(0) | possibly_damaging(0.476) | TCGA-E2-A14P-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Targeted Molecular therapy | trastuzumab | SD |